A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma

Abstract Background Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by reason of their expression of shared tumo...

Full description

Bibliographic Details
Main Authors: Apostolos Sarivalasis, Caroline Boudousquié, Klara Balint, Brian J. Stevenson, Philippe O. Gannon, Emanuela Marina Iancu, Laetitia Rossier, Silvia Martin Lluesma, Patrice Mathevet, Christine Sempoux, George Coukos, Urania Dafni, Alexandre Harari, Michal Bassani-Sternberg, Lana E. Kandalaft
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Journal of Translational Medicine
Subjects:
Ovarian cancer
Dendritic cell vaccine
Neoantigen
Neoepitope
Cancer immunotherapy
Cyclophosphamide
Online Access:http://link.springer.com/article/10.1186/s12967-019-02133-w

Internet

http://link.springer.com/article/10.1186/s12967-019-02133-w

Similar Items